Current Advances Of Stem Cell-based Therapy For Kidney Diseases

Abstract

Kidney diseases are a prevalent health problem around the world. Multidrug therapy used in the current routine treatment for kidney diseases can only delay disease progression. None of these drugs or treatments can reverse the progression to end-stage disease. Therefore, exploring novel therapeutics to improve patients’ quality of life and possibly cure, reverse, or alleviate kidney disease is crucial. Stem cells have promising potential as a form of regenerative medicine for kidney diseases due to their unlimited replication and their ability to differentiate into kidney cells in vitro. Mounting evidence from the administration of stem cells in an experimental kidney disease model suggested that stem cell-based therapy has therapeutic or renoprotective effects to attenuate kidney damage while improving the function and structure of both glomerular and tubular compartments. This review summarises the current stem cell-based therapeutic approaches to treat kidney diseases, including the various cell sources, animal models, and in vitro studies. The challenges of progressing from proof-of-principle in the laboratory to widespread clinical application and the human clinical trial outcomes reported to date are also highlighted. The success of cell-based therapy could widen the scope of regenerative medicine in the future. 

Key Words

Stem cells; Kidney regeneration; Kidney disease; Mesenchymal stem cells; Embryonic stem cells; Induced pluripotent stem cells

Core Tip

Stem cells have the potential to be the next regenerative medicine to treat kidney diseases. There is mounting evidence suggesting that stem cell-based therapy has renoprotective effects to attenuate kidney damage while improving kidney function. This review summarises the current stem cell-based therapy approaches to treat kidney diseases in experimental models and the outcomes from human clinical trials reported to date.

INTRODUCTION 

Kidney disease is a prevalent global health problem. A new analysis suggested that the global prevalence of chronic kidney disease (CKD) in the year 2017, was 9.1% (697.5 million cases). The World Health Organization has estimated that as many as 5 to 10 million people die annually from kidney diseases worldwide. By 2040, CKD is projected to be the fifth leading cause of death worldwide.

In recent years, research into the use of stem cells and a Chinese herbal remedy for the treatment of kidney diseases has gained great attention. The main mechanism of the two therapies is to promote the repair of injured renal tissues and protect the remaining renal functions. 

The Chinese herbal remedy,cistanche, has been used in traditional Chinese medicine to treat various chronic kidney diseases since ancient times. It is reported that cistanche has the potential to reduce inflammation, reduce kidney fibrosis, and promote the synthesis of extracellular matrix components. It has been revealed that these effects are due to its bioactive components, including many phenolic substances, triterpenoids, and coumarins.

Click On Cistanche Tubulosa For Kidney Disease 

FOR MORE INFORMATION: david.deng@wecistanche.com

On the other hand, stem cell technology has caused a revolution in medical practice. Research has demonstrated that stem cells can differentiate into various types of renal cells and perform therapeutic activities, including protecting the remaining functional renal tissues, slowing down tissue fibrosis, and repairing damaged renal tissues.

Ultimately, the combination of traditional Chinese medicine with modern science could be the key to treating various kidney diseases. This strategy has gradually been accepted by the medical community and studies have already shown that the combined therapy of cistanche and stem cell treatment may considerably reduce the mortality rate of kidney diseases. 

In conclusion, the use of cistanche and stem cell treatment in the treatment of kidney diseases shows great potential and requires further research. The combined therapy of the two treatments could provide an improved treatment option for those facing kidney diseases.

To date, there has been no significant breakthrough in the medical treatment of kidney diseases, whereas the current routine treatment consisting of multidrug therapies can only delay the disease’s progression. These drugs cannot reverse the progression into end-stage kidney disease (ESKD). The current therapeutic repertoire to prolong the lifespan of ESKD patients is limited to kidney replacement

therapy, dialysis, or organ transplantation. Due to the high medical cost involved in dialysis therapy, which also compromises the patient’s quality of life, dialysis is not an ideal solution. This is primarily because dialysis does not restore or substitute all kidney functions. Meanwhile, the severe shortage of organ donors and potential organ rejection risks limit the practice of kidney transplantations. Therefore, it is crucial that medical researchers explore novel therapeutics to improve the quality of life for patients with kidney diseases and to potentially cure, reverse, or alleviate kidney disease.

Stem cells are defined as cells capable of self-renewal and can differentiate into a variety of cell types. Moreover, stem cells possess cellular plasticity and easily expand in vitro, which are the beneficial properties of stem cell therapy. Stem cells have been extensively explored in treating cardiac, neuron, vascular, immunological, and kidney diseases. In some countries, there are stem cell therapies based on mesenchymal stem cells (MSCs), which are available as commercial products approved by local regulatory agencies for specific diseases or health indications. Thus, this form of intervention can pave the way for the next regenerative medicine for human diseases. Figure 1 showed an overview of stem cell-based strategies to treat kidney disease.

This present article reviews stem cell-based therapy in kidney regeneration based on animal models and in vitro studies, as well as discusses its potential for clinical application and the challenges in translating from animal models to clinical application.

EMBRYONIC STEM CELLS 

Embryonic stem cells (ESCs) are pluripotent cells with unlimited differentiation potentials. Several research groups have demonstrated that mouse ESCs can integrate into kidney compartments, suggesting the potential value of stem cells in kidney repair. Implantation of ESCs directly into mouse embryonic kidney culture resulted in ESC-derived tubules and proximal tubular cells. Exposing ESCs to specific inducers or factors also caused the induction of cells to differentiate into kidney lineage cells in vitro. Kim and Dressler induced mouse ESCs to differentiate into renal progenitor cells and then incorporated these cells into the tubular epithelial by injection into embryonic kidney cultures. In another study, when intact rat kidneys were decellularised in this manner, the kidney’s intricate architecture was preserved, and the seeded ESCs could proliferate within the glomerular, vascular, and tubular structures. Vazquez-Zapien et al further reported that after mice with cisplatin-induced kidney failure received mouse ESCs via injection, the mortality rate decreased significantly and prevented further disease-related histological deterioration.

Figure 1 Overview of stem cell-based strategies to treat kidney disease. Different types of stem cells were explored for their ability to treat kidney disease. One strategy was to direct the differentiation of stem cells into kidney component cells in vitro or in vivo to replace the injured or damaged cells. Other strategies were to transplant stem cells or stem cell-derived extracellular vesicles to generate paracrine effect/endocrine effect and to use kidney organoid formation to replace whole kidney organs. 

The kidney, on another hand, is a very complex organ made of several cell types (Figure 2). Therefore, it is an intricate organ to reconstruct. Many researchers have worked on a protocol to induce ESCs into generating complex structures to resemble kidneys with multiple renal cell types and are capable of self-organization, termed organoid. Tan et al reported that mouse ESCs-derived nephron progenitors, aggregated with primary ureteric bud, formed kidney organoids with full nephron structures.

Despite its clinical potential, the risk of tumorigenicity, together with legal and ethical concerns, continue to hinder the development of SC-based therapies. Additionally, ESC-derived differentiated cells are allogeneic in nature and can therefore express specific surface proteins to trigger the recipient’s immune system. Therefore, acute and chronic rejection, or graft vs host disease, can occur due to the use of allografts if they fail to achieve immunocompatibility with the recipient.

INDUCED PLURIPOTENT STEM CELLS

Induced pluripotent stem cells (iPSCs) share many regenerative properties with ESCs. In 2006, Takahashi and Yamanaka showed that mouse adult fibroblasts can be reprogrammed into iPSCs, by introducing four transcription factors (OCT4, SOX2, KLF4, and c-MYC). This was a breakthrough finding that became a landmark in stem cell research. The development of iPSCs-based therapies could overcome the specific issues related to the use of ESCs, such as ethical concerns due to the cells’ source and the potential of cell rejection by the recipient patient.

The use of ESCs has its controversies due to certain parties who are of the opinion that destroying an embryo for its ESCs is akin to killing an unborn child. Hence, iPSCs are an attractive alternative to ESC-like stem cells as the iPSCs can be generated from adult cells. These cells also retain the genetic background and peculiar epigenetic memory of their parent cell, thus possibly avoiding any strong immune response. To date, iPSCs have been generated from fibroblasts, umbilical cord blood, peripheral blood, and keratinocytes. Researchers have also successfully generated iPSCs from mesangial cells, renal tubular cells, and renal epithelial cells. Reprogrammed iPSCs from kidney cells are believed to potentially aid in the study of genetic kidney diseases, which may lead to the development of novel therapies.

The potential of iPSCs in kidney regeneration has been explored, including establishing unique methods to stimulate human iPSCs to differentiate into kidney lineages or three-dimensional structures of the kidney. Toyohara et al established a multistep differentiation protocol to induce human iPSCs to differentiate into renal progenitors capable of constructing three-dimensional proximal renal tubule-like structures in vitro. The same group subsequently discovered that renal subcapsular transplantation of these human iPSC-derived renal progenitors ameliorated the acute kidney injury (AKI) in the animal model.

In addition to relying on the differentiation ability of iPSCs, researchers have also used the renotropic factors produced by the iPSCs in kidney regeneration. Transplantation of iPSCs in a murine model with ischemic AKI, reduced the expression of oxidative substances, pro-inflammatory cytokines, and apoptotic factors, resulting in eventual improvement in survival. Additionally, Tarng et al demonstrated that iPSCs-derived conditioned medium attenuated AKI and significantly improved survival in an animal model. 

From recent developments, iPSCs can now be directed to differentiate and generate kidney organoids resembling the human kidney in vitro. An artificially created human kidney can be applied in regenerative medicine, and in developmental, toxicity, and disease models. Furthermore, using patients' own iPSCs to generate high-quality kidney organoids enables drug validation in a patient-specific manner. This is contributed by the tight correlation between the patient’s individual genetic background and drug responsiveness. Melissa H Little’s group had successfully generated human iPSCs-derived kidney organoids that had all the anticipated kidney cell types. These organoids possessed nephrons segmented into the glomerulus, proximal tubule, a loop of Henle, and distal tubule along with the collecting duct, endothelial network, and renal interstitium. Meanwhile, similarly, IzpisuaBelmonte’s group had also generated a kidney organoid containing glomeruli with podocytes, proximal and distal tubule cells, and endothelial cells. Morizane et alreported several differentiation protocols for creating kidney organoids with epithelial nephron-like structures. These organoids expressed the markers for podocytes, proximal tubules, loops of Henle, and distal tubules. 

Other research groups reported that iPSCs derived from various cell types are not identical in their differentiation capacity. This is likely to happen because iPSCs maintain the epigenetic memory of their parental cells. Therefore, renal parenchymal cells may be a better candidate than cells from other tissues for reprogramming to treat kidney diseases.

ENDOTHELIAL PROGENITOR CELLS 

Endothelial progenitor cells (EPCs) have essential roles in maintaining vascular integrity and in repairing any form of endothelial damage. EPCs can be isolated from different cell sources, mainly from the readily available bone marrow, cord blood, and peripheral blood. The beneficial effects of EPCs-based therapies have been shown in studies performed using different models of kidney diseases such as AKI, CKD, and renal artery stenosis. In an animal model of renal ischemia/ reperfusion (I/R)-induced AKI, renal artery-derived EPC-like cells integrated into the endothelium after AKI, led to decreased levels of serum creatinine (SCr) and albuminuria while blood flow improved. Patschan et al further demonstrated that the systemic injection of peripheral blood-derived early EPCs decreased SCr, ameliorated interstitial fibrosis, and subsequently reduced the progression to CKD after AKI.

The possible effect of EPC treatment on CKD progression was studied in an animal model. In this study, bone marrow-derived EPCs that were homed into the injured kidney prevented the inflammatory condition from adversely affecting the kidney, and successfully preserved kidney function and structure. Huang et al demonstrated a rodent model injected with peripheral blood-derived EPCs and observed effective inhibition of the propagation of CKD and the deterioration of kidney function. The injected cells enhanced angiogenesis and blood flow and had anti-oxidative capacity while suppressing inflammation, oxidative stress, apoptosis, and fibrosis. Meanwhile, in renal artery stenosis models, peripheral blood derivedEPCs demonstrated renoprotective effects after injection into the stenotic kidney, by improving microvascular density and kidney functions along with diminishing fibrosis. 

MSCs

MSCs, or as recently referred to as mesenchymal stromal cells, were first discovered by Friedenstein and his colleagues from bone marrow. Over the years, researchers have found that MSCs can be isolated from various organs or tissues, such as adipose tissue, umbilical cord, placenta, peripheral blood, amniotic fluid, and skeletal muscles. 

Bone marrow is the most commonly used source for MSCs in clinical treatments, including treating kidney diseases. However, the use of bone marrow derived-MSCs (BM-MSCs) became limited because of a high degree of viral exposure, and the cell proliferation/differentiation capability significantly decreases as the donor’s age increases. Therefore, researchers began exploring other types of MSCs for kidney regeneration. Among the many sources, adipose tissue-derived MSCs (AD-MSCs) and umbilical cord-derived MSCs (UC-MSCs) have become desirable candidates because a large amount of the MSCs can be obtained using relatively minimal invasive procedures.

In the field of kidney disease, MSCs are among the most efficient type of cell population for activating regeneration in a damaged kidney. Pre-clinical reports have demonstrated the therapeutic potential of MSCs in animal models of AKI and CKD. According to a systematic review of more than 70 articles, MSCs are among the most effective cell populations to treat experimental CKD. Meanwhile, in a meta-analysis involving animal models of chronic and AKI, MSCs led to kidney regeneration despite the variable modes of administration (arterial, venous, or renal). There is evidence suggesting the beneficial effects of MSCs in blocking AKI-CKD transition, a term used to describe an incomplete recovery from AKI resulting in long-term functional deficits, such as CKD. 

In an experiment performed by Brasile et al, when chemically damaged human kidneys were perfused ex vivo with MSCs for 24 h, kidney regeneration was documented. The MSCs-based treatment caused the kidneys to synthesize significantly lower levels of inflammatory cytokines. Compared to exsanguinous metabolic support perfusion alone, there was a significant increase in the number of renal cells undergoing mitosis in the MSCs-treated kidneys. 

Numerous studies have demonstrated that MSCs can either differentiate into renal cells in general or specifically into kidney component cells such as renal epithelial cells, mesangial cells, and endothelial cells. 

BM-MSCs

Many studies have demonstrated the efficacy of BM-MSCs in the treatment of kidney disease using animal models of AKI, podocyte injury, and glomerulonephropathy. Morigi et al are among the first groups to demonstrate the renoprotective role of BM-MSCs and documented the therapeutic potential of human BM-MSCs in the treatment of kidney diseases, leading to survival in animal models. Transplantation of human BM-MSCs into cisplatin-induced AKI mice resulted in markedly improved kidney function and recovery by accelerating tubular proliferation and reducing the number of tubules affected by apoptosis, necrosis, and tubular lesions. A similar form of protection was conferred by injected BM-MSCs in a glycerol-induced pigment nephropathy model and I/R-induced AKI. More importantly, infused BM-MSCs have been shown to enhance kidney functional recovery even when administered 24 h after the injury. Furthermore, BM-MSCs were more effective in treating AKI in the animal model compared to candesartan, which is an angiotensin II blocker. In essence, there is good evidence that when MSCs are transplanted in toxic and ischemic animal models, the cells protect the animals against AKI and accelerate the recovery phase.

BM-MSCs have also shown promise in the treatment of CKD in animal models. BM-MSCs prevented the loss of peritubular capillaries and slowed down the progression of proteinuria (protein in the urine). During the initial phase of the immune response before the onset of CKD, these cells also reduced kidney fibrosis. According to histological analysis of a rat model with CKD, BM-MSCs reduced glomerulosclerosis, resulting in the preservation of kidney function and attenuation of kidney injury. Additionally, when animal models with CKD were treated with BM-MSCs, there was reduced progression of proteinuria and scarce engraftment of these cells in the kidneys. These observations suggested that these beneficial effects were probably caused by cytokines or growth factors, which are also known as the paracrine secretion of mediators.

In addition to the ability of BM-MSCs to differentiate into renal cells, more recent reports suggested that BM-MSCs exert protective and regenerative effects on kidneys by their paracrine anti-inflammatory, anti-fibrotic, and vascularisation properties. According to reports, BM-MSCs can transfer biological cues via the secretion of extracellular vesicles (EVs) to promote regenerative processes in injured renal cells.

Several studies investigated the effects of BM-MSCs in experimental models of kidney organ transplantation. Most studies focused on the intervention’s efficacy through prolonged graft survival and inhibition of the rejection process. Given the advantage of BM-MSCs having low immunogenicity and immunoregulatory properties, BM-MSCs can reduce alloimmune injury and immune suppression-related side effects to optimize the preservation of the transplanted kidney’s functions. 

AD-MSCs

AD-MSCs are highly abundant in adipose tissues and can be easily extracted via liposuction, a method that is widely used in the clinical setting. Adipose tissue may become the preferred source of MSCs due to its less invasive procurement and higher MSCs concentration than those found in the bone marrow. Their allergenic transplantation via the intra-renal route contributed to a low degree of necrosis but caused higher vascularisation of the renal parenchyma in Wister rats. There are reports on the therapeutic effect of AD-MSCs in AKI-induced animal models. Kim et al have demonstrated that AD-MSCs reduced apoptotic cell death while simultaneously reducing the activation of p53, c-Jun NH2-terminal kinase, and extracellular signal-regulated kinase, which are inflammation-related molecules. These effects resulted in the increased survival rate of the AKI-induced animals. Katsuno et al further discovered that human AD-MSCs cultured in low serum secreted high levels of hepatocyte and vascular endothelial growth factors. When these cells were transplanted into AKI-induced rats, they enhanced the attenuation of kidney damage. Even though adipose tissue is a good source of MSCs, AD-MSCs have been less effective in proliferative and kidney regenerative activities compared to BM-MSCs. 

UC-MSCs

The easy collection of UC-MSCs provides a new abundant source of MSCs. The usage of UC-MSCs transforms medical waste into a beneficial product with clinical applications. Compared to MSCs from other sources, UC-MSCs have low immunogenicity, thus preventing the occurrence of immune rejection in allogeneic transplantation. Moreover, UC-MSCs have a greater proliferation capacity compared to BM-MSCs and AD-MSCs. UC-MSCs also show no sign of senescence over several passages, so mass cell production of UC-MSCs is highly possible without causing the loss of cell potency.

Other sources of MSCs 

In addition to BM-MSCs, AD-MSCs, and UC-MSCs, researchers have also used other types of MSCs that are less commonly studied for kidney regeneration studies. The efficacy of cord blood-derived MSCs (CB-MSCs) administration in the restoration of kidney function had been reported in animal AKI models. This study demonstrated that CB-MSCs promoted kidney regeneration and prolonged the survival of the animal. Based on this study, the paracrine action of CB-MSCs on the tubular cells may have been mediated by the reduction of oxidative stress, apoptosis, and inflammation. Hauser et al and George et al found that amniotic fluid-derived MSCs (AF-MSCs) possess the same characterization as BM-MCSs, facilitating functional and structural improvement in a rat model of CKD. Sedrakyan et al showed the injection of AF-MSCs in mice delays the progression of renal fibrosis. Meanwhile, in a CKD-induced rat model in a study by Cetinkaya et al, transplanted placenta-derived MSCs (PL-MSCs) alleviated kidney damage and inhibited fibrosis-induced apoptosis. PL-MSCs were also used to treat kidney injury and inflammation in lupus nephritis (LN) mice. 

STEM CELL-DERIVED EVs 

EVs are small membrane vesicles secreted by various cells and found in most body fluids. This review uses the general term, EVs, because there is no method to precisely identify the vesicles. EVs can be classified into three major categories, which are exosomes, microvesicles, and apoptotic bodies. In the current context, researchers suggest that EVs could be transferred to injured cells to restrain tissue injury, reduce inflammation, inhibit apoptosis, and induce cell cycle re-entry of resident cells, all of which lead to cell proliferation, tissue self-repair, and regeneration. Upon administration with a therapeutic regimen, EVs will mimic stem cells' effects in various experimental models.

The use of stem cell-derived EVs could have multiple advantages in clinical application including bypassing most of the safety concerns related to stem cell therapy, such as cellular contamination with oncogenic cells, tumorigenicity, and emboli formation after transplantation. Similarly, EVs also enable a wide range of potential manipulations to carrier molecules for improvements in delivery and desired effects. EVs can also be safely stored in medical facilities without losing any of their functions.

Several studies had provided convincing evidence of the regenerative potential of EVs released by stem cells, specifically MSCs, in different models of kidney injury. In vitro studies have demonstrated the potential of MSCs-derived EVs to transfer mRNA, miRNA, and proteins to renal cells. Currently, this cell-free therapy is being studied in animal models of AKI and CKD. Intravenous MSC-derived EVs exert renoprotective effects by reducing renal cell damage and apoptosis while enhancing the proliferation of the renal cells. These effects lead to improved kidney function, similar to those induced by MSCs, as reported in rats injected with EVs from EPCs and iPSCs. 

When a patient living with ESKD undergoes kidney transplantation, the patient’s quality of life significantly improves. Nevertheless, chronic allograft nephropathy limits organ survival, eventuating in the patient having to undergo kidney transplantation more than once in a lifespan. The administration of EVs after kidney transplantation was found to ameliorate I/R injury in both the acute and chronic stages, favor tolerance and prolong allograft survival.

The preconditioning of a kidney with stem cells-derived EVs may also conveniently limit tissue damage caused by chronic allograft nephropathy. Evidence showed that the MSCs-derived EVs delivered in the perfusate during organ cold perfusion for 4 h protected the kidney from reperfusion damage and can preserve the organ’s enzymatic machinery, which is essential for cell viability.

TRANSLATION FROM ANIMAL MODEL TO HUMAN CLINICAL APPLICATION: THE CHALLENGES

Despite numerous animal experiments to demonstrate the effectiveness of stem cell therapy in kidney disease, outcomes from those animal models were unsuccessfully reproduced in human clinical studies in entirety. The failure to translate the promising results from an animal experiment, which has a sound and standardized design and conduct, to a clinical application happens due to variations in the animal model and human physiology. 

Human kidney diseases are typically artificially induced in the animal model. The induced injury is generally acute, and unphysiological, and cannot epitomize the human kidney diseases' complex pathological features. It is thus difficult to precisely simulate or predict the response of human kidney disease to treatment by using an animal model. CKD animal experiments are insufficient to reflect the disease’s conditions because other factors such as age, sex, and comorbidities are not represented. CKD patients may also have comorbidities involving multiple organs and functions that further aggravate the pathological processes underlying CKD. In the animal model, however, these complications were not taken into account.

Both humans and animals may have the same protein functions but there are species-specific differences in the molecular regulation of genes. This causes difficulty in extrapolating an outcome from an animal gene analysis to the physiological conditions in the human body. The differences between the animals' and humans' immune systems are another reason for the failure to translate therapeutics with promising outcomes in vivo studies into a clinical application with potential. 

ADVANCING CLINICAL TRIALS OF STEM CELLS FOR KIDNEY DISEASE 

Up until March 2021, more than 40 clinical trials, either ongoing or completed, involving the use of stem cell-based therapy in the treatment of kidney diseases have been registered in the United States National Library of Medicine (ClinicalTrials.gov). Most of these stem cell clinical trials for kidney disease use MSCs in their approach. Table 1 showed the completed clinical trials of MSC- and EPC-based therapies in kidney diseases. 

The first few trials using MSCs from different tissue sources (bone marrow, adipose, umbilical cord, etc.) either autologously or allogeneic ally suggested that these cells can be given safely to humans. However, the efficacies of MSCs to treat kidney diseases have mixed results. In one study, patients who had a high risk of postoperative AKI and underwent cardiac surgery concurrently received allogeneic BM-MSCs. The patients had a shorter hospital stay and did not need readmission. The administered BM-MSCs did not have adverse effects and protected the patients against early and late post-surgery kidney function deterioration. However, Swaminathan et al reported a contrasting finding, whereby the administration of allogeneic MSCs did not decrease the time to recovery of kidney function in patients with a developed stage of AKI after cardiac surgery. They also did not detect any significant differences between the group treated with allogeneic MSCs and the group treated with placebo in the 30-day all-cause mortality study. While the rates of adverse events did not differ between groups, the MSC infusion was safe and well-tolerated.

More human trials have been conducted using MSCs to treat CKD. A pilot study assessing the safety and clinical feasibility of autologous administration of AD-MSCs for patients with CKD reported that the cells were safe and did not exert any adverse effects. At the same time, improvement in urinary protein excretion was observed. However, Makhlough et al reported no significant changes in estimated glomerular filtration rate and SCr during the 18 mo of follow-up after autologous BMMSCs were transplanted in these CKD patients.

In studies involving the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) with MSCs, the cells were investigated for their therapeutic benefits. Sun L and team conducted phase I/II clinical trials to examine the effects of allogeneic BM-MSCs and UC-MSCs infusions in patients with primary and refractory SLE. They found that the infusion of either allogeneic BM-MSCs or UC-MSCs was safe and well-tolerated. Besides improving the SLE Disease Activity Index and kidney function, the level of proteinuria declined 24 h after the MSCs transplantation. Furthermore, among the SLE patients, allogeneic MSCs transplantation resulted in renal remission for active LN patients within a 12-mo follow-up period. Barbado et al in their pilot study also reported a dramatic improvement in proteinuria levels during the first-month post-treatment. The ameliorations were sustained throughout the follow-up period of nine months. Conversely, a recent multicentre randomized, double-blind controlled trial showed that UC-MSCs have no apparent additional effects over and above standard immunosuppression therapy. 

Given the immunomodulatory properties of MSCs, these cells have been transplanted in patients who received kidney transplants to promote immune tolerance to kidney transplantation in the setting of peri-transplant T cell-depleting induction therapy. Reports showed that transplanted MSCs were safe and without major side effects even over a long-term follow-up. Additionally, there was an increased proliferation of Treg noted, an increment in regulatory T cell proportion, and improved early allograft function. Simultaneously, the transplanted MSCs also controlled memory CD8+ T cells’ functions and reduced donor-specific CD8+ T cell cytolytic response. Furthermore, MSCs infusion showed a lower incidence of acute rejection leading to a decreased risk of opportunistic infections and faster kidney function recovery than the controls. These preliminary data suggest that transplanted MSCs are safe, well-tolerated, and can suppress host immune responses after kidney transplants with the combination of the appropriate immunosuppressive regimen.

A recent phase I trial using autologous CD34+ EPCs in treating CKD at stage III or IV has been reported. Yip HK and team demonstrated that intra-renal arterial transfusion of CD34+ EPCs was safe and well-tolerated. However, when the efficacy in the phase II randomized controlled trial was further investigated, the infused EPCs did not offer additional benefit to patients with CKD up to a follow-up period of 12 months. Despite the less encouraging outcome, it is worth noting that the unfavorable clinical outcomes, such as dialysis or death, were significantly lower in the treatment group than those in the control group. Currently, many clinical trials are still ongoing and will provide more insights into and possibly further support these achievements with cell-based therapy for kidney diseases. 

CONCLUSION 

Although stem cell therapies in kidney regeneration from in vitro and preclinical studies are promising, and an encouraging safety profile have been demonstrated in early-phased human clinical trials, these cell-based therapies are yet to be translated into more significant proof of clinical efficacy. The side effects of stem cell therapies on kidney diseases still need further investigation, as the preliminary results available still lack long-term follow-up data. Some concerns about the use of live stem cells should be kept in consideration. EVs should also be evaluated as a possible alternative to live stem cells. The use of stem cells-derived EVs that can mimic their parental cells' effects in renoprotection could be pursued. Nevertheless, it appears that stem cell therapy will have a great future in the field of kidney regeneration. Further clarification will be gained on the stem cells' protective mechanisms in the treatment of kidney diseases through further understanding of the mechanisms of stem cells’ actions in vivo. The success of this new cell-based therapy could genuinely change the scope of the future of regenerative medicine. 

REFERENCES 

1. Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol 2020; 16: 251

2. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395: 709-733 

3.Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 2018; 96: 414-422D 

4. Luyckx VA, Al-Aly Z, Bello AK, Bellorin-Font E, Carlini RG, Fabian J, Garcia-Garcia G, Iyengar A, Sekkarie M, van Biesen W, Ulasi I, Yeates K, Stanifer J. Sustainable Development Goals relevant to kidney health: an update on progress. Nat Rev Nephrol 2021; 17: 15-32

5. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015; 385: 1975-1982 

6. Vanholder R, Lameire N, Annemans L, Van Biesen W. Cost of renal replacement: how to help as many as possible while keeping expenses reasonable? Nephrol Dial Transplant 2016; 31: 1251- 1261

7. Saidi RF, Hejazii Kenari SK. Challenges of organ shortage for transplantation: solutions and opportunities. Int J Organ Transplant Med 2014; 5: 87-96

8.Rodríguez-Fuentes DE, Fernández-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Saldaña HA. Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review. Arch Med Res 2021; 52: 93-101

9. Chin SP, Maskon O, Tan CS, Anderson JE, Wong CY, Hassan HHC, Choor CK, Fadilah SAW, Cheong SK. Synergistic effects of intracoronary infusion of autologous bone marrow-derived mesenchymal stem cells and revascularization procedure on the improvement of cardiac function in patients with severe ischemic cardiomyopathy. Stem Cell Investig 2021; 8: 2

10. Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K, Karp JM. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv 2020; 6: eaba6884

11 Narayanan K, Schumacher KM, Tasnim F, Kandasamy K, Schumacher A, Ni M, Gao S, Gopalan B, Zink D, Ying JY. Human embryonic stem cells differentiate into functional renal proximal tubular-like cells. Kidney Int 2013; 83: 593-603

12 Takasato M, Er PX, Becroft M, Vanslambrouck JM, Stanley EG, Elefanty AG, Little MH. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol 2014; 16: 118-126

13 Kim D, Dressler GR. Nephrogenic factors promote the differentiation of mouse embryonic stem cells into renal epithelia. J Am Soc Nephrol 2005; 16: 3527-3534 

14 Ross EA, Williams MJ, Hamazaki T, Terada N, Clapp WL, Adin C, Ellison GW, Jorgensen M, Batich CD. Embryonic stem cells proliferate and differentiate when seeded into kidney scaffolds. J Am Soc Nephrol 2009; 20: 2338-2347 

15 Vazquez-Zapien GJ, Martinez-Cuazitl A, Rangel-Cova LS, Camacho-Ibarra A, Mata-Miranda MM. Biochemical and histological effects of embryonic stem cells in a mouse model of renal failure. Rom J Morphol Embryol 2019; 60: 189-194 

16 Liu D, Cheng F, Pan S, Liu Z. Stem cells: a potential treatment option for kidney diseases. Stem Cell Res Ther 2020; 11: 249 

17 Geuens T, van Blitterswijk CA, LaPointe VLS. Overcoming kidney organoid challenges for regenerative medicine. NPJ Regen Med 2020; 5: 8

18 Tan Z, Shan J, Rak-Raszewska A, Vainio SJ. Embryonic Stem Cells Derived Kidney Organoids as Faithful Models to Target Programmed Nephrogenesis. Sci Rep 2018; 8: 16618 

19 Li SC, Zhong JF. Twisting immune responses for allogeneic stem cell therapy. World J Stem Cells 2009; 1: 30-35

20 Chhabra P, Brayman KL. The use of stem cells in kidney disease. Curr Opin Organ Transplant 2009; 14: 72-78

21 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676 

22 Erdlenbruch F, Rohwedel J, Ralfs P, Thomitzek A, Kramer J, Cakiroglu F. Generation of induced pluripotent stem cells (iPSCs) from human foreskin fibroblasts. Stem Cell Res 2018; 33: 79-82 

23 Fernandes S, Shinde P, Khan N, Singh S, Vardhan S, Nair V, Kale V, Limaye L. Derivation of human iPSC line NCCSi002-A from umbilical cord blood (UCB) CD34+cells of the donor from Indian ethnicity. Stem Cell Res 2018; 26: 80-83 

24 Kim Y, Rim YA, Yi H, Park N, Park SH, Ju JH. The Generation of Human Induced Pluripotent Stem Cells from Blood Cells: An Efficient Protocol Using Serial Plating of Reprogrammed Cells by Centrifugation. Stem Cells Int 2016; 2016: 1329459 

25 Vlahos K, Sourris K, Mayberry R, McDonald P, Bruveris FF, Schiesser JV, Bozaoglu K, Lockhart PJ, Stanley EG, Elefanty AG. Generation of iPSC lines from peripheral blood mononuclear cells from 5 healthy adults. Stem Cell Res 2019; 34: 101380

26 Re S, Dogan AA, Ben-Shachar D, Berger G, Werling AM, Walitza S, Grünblatt E. Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes - A Tool to Study Neurodevelopmental Disorders as ADHD. Front Cell Neurosci 2018; 12: 321 

27 Song B, Niclis JC, Alikhan MA, Sakkal S, Sylvain A, Kerr PG, Laslett AL, Bernard CA, Ricardo SD. Generation of induced pluripotent stem cells from human kidney mesangial cells. J Am Soc Nephrol 2011; 22: 1213-1220 

28 Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, Bao X, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 2012; 7: 2080-2089

29 Steinle H, Weber M, Behring A, Mau-Holzmann U, von Ohle C, Popov AF, Schlensak C, Wendel HP, Avci-Adali M. Reprogramming of Urine-Derived Renal Epithelial Cells into iPSCs Using srRNA and Consecutive Differentiation into Beating Cardiomyocytes. Mol Ther Nucleic Acids 2019; 17: 907-921

30 Su J, Wang J, Wang L, Li T, Wang H, Shen J, Zhang J, Lin W, Huang J, Liang P. Generation of five induced pluripotent stem cell lines with DMD/c.497G > T mutation from renal epithelial cells of a Duchenne muscular dystrophy patient and a recessive carrier parent. Stem Cell Res 2020; 49: 102021

31 Mae SI, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K, Nakayama N, Cowan CA, Aoi T, Ogawa S, McMahon AP, Yamanaka S, Osafune K. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun 2013; 4: 1367

32 Araoka T, Mae S, Kurose Y, Uesugi M, Ohta A, Yamanaka S, Osafune K. Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods. PLoS One 2014; 9: e84881

33 Lam AQ, Freedman BS, Morizane R, Lerou PH, Valerius MT, Bonventre JV. Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. J Am Soc Nephrol 2014; 25: 1211-1225

34 Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, Nishinakamura R. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell 2014; 14: 53-67

35 Toyohara T, Mae S, Sueta S, Inoue T, Yamagishi Y, Kawamoto T, Kasahara T, Hoshina A, Toyoda T, Tanaka H, Araoka T, Sato-Otsubo A, Takahashi K, Sato Y, Yamaji N, Ogawa S, Yamanaka S, Osafune K. Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice. Stem Cells Transl Med 2015; 4: 980-992

36 Lee PY, Chien Y, Chiou GY, Lin CH, Chiou CH, Tarng DC. Induced pluripotent stem cells without c-Myc attenuate acute kidney injury via downregulating the signaling of oxidative stress and inflammation in ischemia-reperfusion rats. Cell Transplant 2012; 21: 2569-2585

37 Tarng DC, Tseng WC, Lee PY, Chiou SH, Hsieh SL. Induced Pluripotent Stem Cell-Derived Conditioned Medium Attenuates Acute Kidney Injury by Downregulating the Oxidative StressRelated Pathway in Ischemia-Reperfusion Rats. Cell Transplant 2016; 25: 517-530

38 Gupta N, Dilmen E, Morizane R. 3D kidney organoids for bench-to-bedside translation. J Mol Med (Berl) 2021; 99: 477-487

39 Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis ML, Addario A, Costantini M, Flex E, Ciolfi A, Pizzi S, Bruselles A, Pallocca M, Simone G, Haoui M, Falchi M, Milella M, Sentinelli S, Di Matteo P, Stellacci E, Gallucci M, Muto G, Tartaglia M, De Maria R, Bonci D. Organoids as a new model for improving regenerative medicine and cancer personalized therapy in renal diseases. Cell Death Dis 2019; 10: 201 

40 Romero-Guevara R, Ioannides A, Xinaris C. Kidney Organoids as Disease Models: Strengths, Weaknesses and Perspectives. Front Physiol 2020; 11: 563981

41 Low JH, Li P, Chew EGY, Zhou B, Suzuki K, Zhang T, Lian MM, Liu M, Aizawa E, Rodriguez Esteban C, Yong KSM, Chen Q, Campistol JM, Fang M, Khor CC, Foo JN, Izpisua Belmonte JC, Xia Y. Generation of Human PSC-Derived Kidney Organoids with Patterned Nephron Segments and a De Novo Vascular Network. Cell Stem Cell 2019; 25: 373-387.e9

42 Benedetti V, Brizi V, Guida P, Tomasoni S, Ciampi O, Angeli E, Valbusa U, Benigni A, Remuzzi G, Xinaris C. Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery. EBioMedicine 2018; 33: 253-268 

43 Takasato M, Little MH. Making a Kidney Organoid Using the Directed Differentiation of Human Pluripotent Stem Cells. Methods Mol Biol 2017; 1597: 195-206

44 Forbes TA, Howden SE, Lawlor K, Phipson B, Maksimovic J, Hale L, Wilson S, Quinlan C, Ho G, Holman K, Bennetts B, Crawford J, Trnka P, Oshlack A, Patel C, Mallett A, Simons C, Little MH. Patient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic Mechanisms. Am J Hum Genet 2018; 102: 816-831 

45 Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, Wolvetang EJ, Roost MS, Chuva de Sousa Lopes SM, Little MH. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 2015; 526: 564-568 

46 Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol 2015; 33: 1193-1200

47 Hu Q, Friedrich AM, Johnson LV, Clegg DO. Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show a tendency for spontaneous redifferentiation. Stem Cells 2010; 28: 1981-1991 

48 Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, Apostolou E, Stadtfeld M, Li Y, Shioda T, Natesan S, Wagers AJ, Melnick A, Evans T, Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28: 848-855

49 Pfaff N, Lachmann N, Kohlscheen S, Sgodda M, Araúzo-Bravo MJ, Greber B, Kues W, Glage S, Baum C, Niemann H, Schambach A, Cantz T, Moritz T. Efficient hematopoietic redifferentiation of induced pluripotent stem cells derived from primitive murine bone marrow cells. Stem Cells Dev 2012; 21: 689-701 

50 Ozkok A, Yildiz A. Endothelial Progenitor Cells and Kidney Diseases. Kidney Blood Press Res 2018; 43: 701-718

51 Chopra H, Hung MK, Kwong DL, Zhang CF, Pow EHN. Insights into Endothelial Progenitor Cells: Origin, Classification, Potentials, and Prospects. Stem Cells Int 2018; 2018: 9847015

52 Pang P, Abbott M, Chang SL, Abdi M, Chauhan N, Mistri M, Ghofrani J, Fucci QA, Walker C, Leonardi C, Grady S, Halim A, Hoffman R, Lu T, Cao H, Tullius SG, Malek S, Kumar S, Steele G, Kibel A, Freedman BS, Waikar SS, Siedlecki AM. Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. Kidney Int 2017; 91: 129-143

53 Patschan D, Schwarze K, Henze E, Patschan S, Müller GA. The endothelial-to-mesenchymal transition and endothelial cilia in EPC-mediated postischemic kidney protection. Am J Physiol Renal Physiol 2016; 310: F679-F687 

54 Sangidorj O, Yang SH, Jang HR, Lee JP, Cha RH, Kim SM, Lim CS, Kim YS. Bone marrow-derived endothelial progenitor cells confer renal protection in a murine chronic renal failure model. Am J Physiol Renal Physiol 2010; 299: F325-F335 

55 Huang TH, Chen YT, Sung PH, Chiang HJ, Chen YL, Chai HT, Chung SY, Tsai TH, Yang CC, Chen CH, Chang HW, Sun CK, Yip HK. Peripheral blood-derived endothelial progenitor cell therapy prevented the deterioration of chronic kidney disease in rats. Am J Transl Res 2015; 7: 804-824

56 Chade AR, Zhu X, Lavi R, Krier JD, Pislaru S, Simari RD, Napoli C, Lerman A, Lerman LO. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009; 119: 547-557

57 Chade AR, Zhu XY, Krier JD, Jordan KL, Textor SC, Grande JP, Lerman A, Lerman LO. Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells 2010; 28: 1039-1047 

58 Ebrahimi B, Li Z, Eirin A, Zhu XY, Textor SC, Lerman LO. Addition of endothelial progenitor cells to renal revascularization restores medullary tubular oxygen consumption in swine renal artery stenosis. Am J Physiol Renal Physiol 2012; 302: F1478-F1485

59 Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, Ruadkow IA. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2: 83-92 

60 Mahmoudifar N, Doran PM. Mesenchymal Stem Cells Derived from Human Adipose Tissue. Methods Mol Biol 2015; 1340: 53-64

61 Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ, Han ZC. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006; 91: 1017-1026

62 Choo KB, Tai L, Hymavathee KS, Wong CY, Nguyen PN, Huang CJ, Cheong SK, Kamarul T. Oxidative stress-induced premature senescence in Wharton's jelly-derived mesenchymal stem cells. Int J Med Sci 2014; 11: 1201-1207

63 Talwadekar MD, Kale VP, Limaye LS. Placenta-derived mesenchymal stem cells possess better immunoregulatory properties compared to their cord-derived counterparts-a paired sample study. Sci Rep 2015; 5: 15784 

64 Longhini ALF, Salazar TE, Vieira C, Trinh T, Duan Y, Pay LM, Li Calzi S, Losh M, Johnston NA, Xie H, Kim M, Hunt RJ, Yoder MC, Santoro D, McCarrel TM, Grant MB. Peripheral blood-derived mesenchymal stem cells demonstrate immunomodulatory potential for therapeutic use in horses. PLoS One 2019; 14: e0212642 

65 Spitzhorn LS, Rahman MS, Schwindt L, Ho HT, Wruck W, Bohndorf M, Wehrmeyer S, Ncube A, Beyer I, Hagenbeck C, Balan P, Fehm T, Adjaye J. Isolation and Molecular Characterization of Amniotic Fluid-Derived Mesenchymal Stem Cells Obtained from Caesarean Sections. Stem Cells Int 2017; 2017: 5932706

66 Čamernik K, Mihelič A, Mihalič R, Marolt Presen D, Janež A, Trebše R, Marc J, Zupan J. Skeletal muscle-derived mesenchymal stem/stromal cells from patients with osteoarthritis show superior biological properties compared to bone-derived cells. Stem Cell Res 2019; 38: 101465 

67 Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y. Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation, and differentiation. Int J Mol Med 2014; 34: 695-704

68 Mastrolia I, Foppiani EM, Murgia A, Candini O, Samarelli AV, Grisendi G, Veronesi E, Horwitz EM, Dominici M. Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review. Stem Cells Transl Med 2019; 8: 1135-1148 

69 Rota C, Morigi M, Imberti B. Stem Cell Therapies in Kidney Diseases: Progress and Challenges. Int J Mol Sci 2019; 20 

70 Wang Y, He J, Pei X, Zhao W. Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models. Nephrology (Carlton) 2013; 18: 201-208 

71 Sávio-Silva C, Soinski-Sousa PE, Balby-Rocha MTA, Lira ÁO, Rangel ÉB. Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives. Rev Assoc Med Bras (1992) 2020; 66 Suppl 1: s45-s54 

72 Papazova DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA, Verhaar MC. Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis. Dis Model Mech 2015; 8: 281-293 

73 Zhao L, Han F, Wang J, Chen J. Current understanding of the administration of mesenchymal stem cells in acute kidney injury to chronic kidney disease transition: a review with a focus on preclinical models. Stem Cell Res Ther 2019; 10: 385

74 Brasile L, Henry N, Orlando G, Stubenitsky B. Potentiating Renal Regeneration Using Mesenchymal Stem Cells. Transplantation 2019; 103: 307-313

75 Ardeshirylajimi A, Vakilian S, Salehi M, Mossahebi-Mohammadi M. Renal Differentiation of Mesenchymal Stem Cells Seeded on Nanofibrous Scaffolds Improved by Human Renal Tubular Cell Lines-Conditioned Medium. ASAIO J 2017; 63: 356-363 

76 Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM, Camussi G. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med 2004; 14: 1035- 1041 

77 Bussolati B, Hauser PV, Carvalho R, Camussi G. Contribution of stem cells to kidney repair. Curr Stem Cell Res Ther 2009; 4: 2-8 

78 Yuan L, Liu HQ, Wu MJ. Human embryonic mesenchymal stem cells participate in the differentiation of renal tubular cells in newborn mice. Exp Ther Med 2016; 12: 641-648 

79 Baer PC, Bereiter-Hahn J, Missler C, Brzoska M, Schubert R, Gauer S, Geiger H. Conditioned medium from renal tubular epithelial cells initiates differentiation of human mesenchymal stem cells. Cell Prolif 2009; 42: 29-37

80 Wong CY, Chang YM, Tsai YS, Ng WV, Cheong SK, Chang TY, Chung IF, Lim YM. Decoding the differentiation of mesenchymal stem cells into mesangial cells at the transcriptomic level. BMC Genomics 2020; 21: 467

81 Wong CY, Tan EL, Cheong SK. In vitro differentiation of mesenchymal stem cells into mesangial cells when co-cultured with injured mesangial cells. Cell Biol Int 2014; 38: 497-501

82 Zou X, Gu D, Xing X, Cheng Z, Gong D, Zhang G, Zhu Y. Human mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic reperfusion injury and enhance angiogenesis in rats. Am J Transl Res 2016; 8: 4289-4299 

83 Wang C, Li Y, Yang M, Zou Y, Liu H, Liang Z, Yin Y, Niu G, Yan Z, Zhang B. Efficient Differentiation of Bone Marrow Mesenchymal Stem Cells into Endothelial Cells in Vitro. Eur J Vasc Endovasc Surg 2018; 55: 257-265 

84 Zhou S, Qiao YM, Liu YG, Liu D, Hu JM, Liao J, Li M, Guo Y, Fan LP, Li LY, Zhao M. Bone marrow-derived mesenchymal stem cells pretreated with erythropoietin accelerate the repair of acute kidney injury. Cell Biosci 2020; 10: 130 

85 Geng Y, Zhang L, Fu B, Zhang J, Hong Q, Hu J, Li D, Luo C, Cui S, Zhu F, Chen X. Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury via the activation of M2 macrophages. Stem Cell Res Ther 2014; 5: 80 

86 Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M. Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am J Physiol Renal Physiol 2012; 303: F1370-F1381

87 Wong CY, Cheong SK, Mok PL, Leong CF. Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model. Pathology 2008; 40: 52-57

88 Kunter U, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, Floege J. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 2202-2212 

89 Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S, Benigni A, Perico N, Alison M, Remuzzi G. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15: 1794-1804

90 Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008; 26: 2075-2082 

91 Qian H, Yang H, Xu W, Yan Y, Chen Q, Zhu W, Cao H, Yin Q, Zhou H, Mao F, Chen Y. Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int J Mol Med 2008; 22: 325-332 

FOR MORE INFORMATION: david.deng@wecistanche.com